Efficacy and Safety of APSTZD in the Treatment of Insomnia Disorder
222 patients around the world
Available in Brazil
Apsen Farmaceutica S.A.
1Research sites
222Patients around the world
This study is for people with
Sleep disorders
Insomnia
Requirements for the patient
To 64 Years
All Gender
Medical requirements
Participants aged between 18 and 64 years.
Participants diagnosed with insomnia disorder according to the criteria defined by the DSM-V and who report sleep maintenance disorder.
Participants who agree not to use alcoholic beverages during the entire treatment period.
Participants with known hypersensitivity to the active ingredients used during the trial or who have exhibited complex sleep behavior after using them.
Participants with a history of alcohol, substance, or illicit drug abuse disorder in the last 2 years.
Women who are pregnant or breastfeeding, as well as women who have a positive result on a pregnancy test during the screening period of the trial.
Participants diagnosed with severe liver failure.
Sites
UNIFAG - Unidade integrada de farmacologia e gastroenterologia
Estacionamento - Av. São Francisco de Assis, 218 - Jardim Sao Jose, Bragança Paulista - SP, 12917, Brazil
